Sleep Apnea News and Research

RSS

Regular physical activity prevents chronic illness: Surgeon General urged to make outdoor time a health priority

National Wildlife Federation (NWF), more than 200 health, conservation, youth, and other organizations, and 16,300 Americans are urging the new surgeon general to make time outdoors a health priority for children.

4 Feb 2010

Study could lead to non-surgical alternatives for tonsillectomies

Children with obstructive sleep apnea (OSA) may one day be able to have an injection or use a throat spray instead of getting their tonsils removed to cure their snoring, according to a new study from the University of Chicago, which found that a specific gene product may be responsible for the proliferation of adenotonsillar tissue that can cause pediatric OSA.

4 Feb 2010

NewTom VGi mobile 3D Cone Beam CT scanner now at Illinois 3D Mobile Imaging

AFP Imaging and Deborah Vessell, owner of 3D Mobile imaging, are proud to announce the first NewTom VGi mobile 3D Cone Beam CT scanner to operate in the state of Illinois. This adds yet another mobile operation to an ever growing fleet of independently owned mobile Cone Beam CT units across the country which utilizes the NewTom VGi Cone Beam CT.

2 Feb 2010

Study assesses gray matter concentration deficits in multiple brain areas of people with OSA

A study in the Feb. 1 issue of the journal SLEEP found gray matter concentration deficits in multiple brain areas of people with severe obstructive sleep apnea (OSA). The study suggests that the memory impairment, cardiovascular disturbances, executive dysfunctions, and dysregulation of autonomic and respiratory control frequently observed in OSA patients may be related to morphological changes in brain structure.

1 Feb 2010

Obesity related health complications more dangerous than risks associated with bariatric surgery

Bariatric weight-loss surgery may sound dangerous and complicated, but a Geisinger physician warns that the real danger may be a life of obesity.

30 Jan 2010

NovaSom Diagnostic System approved for diagnostic evaluation of adults with OSA

Some 18-20 million Americans are at risk for Obstructive Sleep Apnea (OSA) and of those, only 5 to 10 percent have been diagnosed. Studies prove that fatality is a major risk of undiagnosed and untreated OSA; however, once detected, OSA can be readily and successfully treated.

29 Jan 2010

ASA urges patients to make lifestyle changes before opting for complicated surgeries

At a time of year when people make plans to drop a few pounds, perhaps even consider bariatric surgery, the American Society of Anesthesiologists (ASA) wants to ensure the public has the facts regarding one's weight and the impact it may have on his or her anesthesia experience.

18 Jan 2010

OSA adversely affects glucose control in patients with type 2 diabetes

Obstructive Sleep Apnea (OSA) adversely affects glucose control in patients with type 2 diabetes, according to a study conducted by researchers at the University of Chicago.

18 Jan 2010

Mylan sued in connection with the filing of ANDA with FDA for Armodafinil Tablets

Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Cephalon Inc. and Cephalon France in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Armodafinil Tablets, 50 mg, 150 mg and 250 mg.

12 Jan 2010

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.

7 Jan 2010

Watson Laboratories files ANDA to seek FDA's approval to market Nuvigil

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 50 mg, 100 mg, 150mg, 200 mg, and 250mg strength armodafinil tablets prior to the expiration of patents owned by Cephalon France.

7 Jan 2010

FDA approves minimally invasive procedure for treating benign and malignant tumors

A minimally invasive surgical approach developed by head and neck surgeons at the University of Pennsylvania School of Medicine has been cleared by the U.S. Food and Drug Administration (FDA). The

5 Jan 2010

Erectile dysfunction linked to RLS in older men

A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms.

3 Jan 2010

AGD Web portal offers handy tips on oral health care

This is the time of year when we all make the same old New Year's resolutions. Exercise more. Eat better. Lose weight. What about committing to better dental health?

31 Dec 2009

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].

22 Dec 2009

InHealth to further understand socioeconomic impact of medical devices and diagnostics

As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.

19 Dec 2009

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

Ethicon and Acclarent announce definitive merger agreement

Ethicon, Inc., a Johnson & Johnson company and a worldwide leader in surgical care, and Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT), today announced a definitive merger agreement whereby Ethicon will acquire Acclarent in an all-cash transaction for approximately $785 million net of estimated cash on hand at time of closing.

17 Dec 2009

Being obese increases the risk for developing OSA in adolescents, study shows

A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine shows that being overweight or obese increases the risk for developing obstructive sleep apnea (OSA) in adolescents but not in younger children.

15 Dec 2009

New technique to determine pediatric OSA

Researchers at the University of Chicago have discovered a technique that is able to determine whether a child has obstructive sleep apnea (OSA) or habitual snoring by screening their urine.

7 Dec 2009